DENTSPLY SIRONA Inc. (XRAY) Presents At Baird 2025 Global Healthcare Conference (Transcript)

Dentsply Sirona's CFO, Matthew Garth, outlined the company's strategic priorities at the Baird 2025 Global Healthcare Conference, focusing on revitalizing the U.S. business through significant reinvestment. Key initiatives include a planned increase in R&D spending from approximately 4-5% to 7% of revenue over time, targeting Essential Dental Solutions and accelerated software development, alongside substantial investment in its sales force. The company intends to reallocate resources from corporate overhead to these growth-driving areas, acknowledging that near-term margin expansion will be secondary to these investments, though long-term SG&A and gross margin improvements are targeted. Garth emphasized a commitment to durable decisions, enhancing customer experience, mending distributor relationships, and returning to market growth rates over a three-year horizon, while also confirming the retention of the Wellspect business due to its strong cash flow contribution and lack of suitable divestiture value. The strategy underscores a focus on free cash flow generation, debt reduction, and share repurchases to drive long-term shareholder value within a diversified dental ecosystem.

Analysis

Dentsply Sirona's new leadership is signaling a significant strategic pivot, prioritizing a multi-year turnaround over near-term profitability. The core of the strategy, articulated by CFO Matthew Garth, involves a substantial reallocation of resources from a self-described 'bloated' corporate overhead to growth-driving investments. Key initiatives include a planned increase in R&D spending from its current ~4-5% level to 7% of revenue over time, with a focus on reviving the under-invested Essential Dental Solutions (EDS) and consumables segment and accelerating software development for its DS Core platform. This will be complemented by a material investment in the sales force to address competitive gaps, particularly in the North American implant market. Consequently, management is guiding that operating margin accretion is not an immediate priority, as these investments will suppress near-term results. However, a long-term path to margin improvement is envisioned, targeting a reduction in SG&A to the low 30% range and a gross margin uplift of 'hundreds of basis points' through operational efficiencies like ERP consolidation and SKU rationalization. The overarching goal is to return the company to market-rate growth within three years and repair its brand and customer experience, which management concedes has been damaged, leading to share loss. The strategy is underpinned by a strong focus on free cash flow generation to reduce debt and fund a consistent share repurchase program, which is seen as a core driver of future shareholder returns.

Key Decisions for Investors

• Investors should adopt a long-term perspective, as the new management's strategy explicitly prioritizes heavy reinvestment in R&D and the sales force over near-term margin expansion, framing this as a multi-year turnaround effort.
• Monitor execution on key turnaround metrics, including progress on the R&D spending ramp-up to 7%, evidence of improved U.S. sales channel performance and mended distributor relationships, and tangible cost savings from the planned G&A restructuring.
• Pay close attention to free cash flow generation and the execution of the share repurchase program, as management has identified this as a primary lever for achieving their targeted 8-10% EPS growth and delivering top-quintile total shareholder return.
• While the internal strategy is clear, remain cautious of the highly competitive landscape, as the success of the turnaround is contingent on regaining market share from focused, pure-play competitors in areas like implants and aligners.